https://www.rxtrospect.com/press-releases daily 0.75 2025-01-28 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/3cf03f3a-f738-4f33-a1d5-6cdc40c09ad2/RxTROSPECT+Background+%28664+x+732+px%29.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/cf9a6169-8bdd-4bbd-a320-b8ec1703ae35/RxTROSPECT+-+Product+Logo+for+Analytics.png https://www.rxtrospect.com/press-releases/2025/1/27/enhertu-approved-in-the-us-as-first-her2-directed-therapy-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-disease-progression monthly 0.5 2025-01-28 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/7e8994e5-eace-4409-9713-d7fe41ccd9dd/LinkedIn+Post+Template+Approvals+%26+News+%283%29.png Press Releases - ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/2025/1/22/fda-approves-sotorasib-with-panitumumab-for-kras-g12c-mutated-colorectal-cancer monthly 0.5 2025-01-22 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/a488c935-e62f-41dc-b764-3e25ec27a602/LinkedIn+Post+Template+Approvals+%26+News+%282%29.png Press Releases - FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/2025/1/17/fda-approves-datopotamab-deruxtecan-dlnk-for-unresectable-or-metastatic-hr-positive-her2-negative-breast-cancer monthly 0.5 2025-01-17 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4b94434f-a6ea-40bd-948b-66df90b6e476/LinkedIn+Post+Template+Approvals+%26+News+%281%29.png Press Releases - FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/2025/1/16/fda-approves-acalabrutinib-with-bendamustine-and-rituximab-for-previously-untreated-mcl monthly 0.5 2025-01-17 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/06d00a8e-cca0-4dac-b625-2d381a92629b/LinkedIn+Post+Template+Approvals+%26+News.png Press Releases - FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/bms-receives-eu-approval-for-nivoipi-plus-for-the-first-line-treatment-of-adult-patients-with-microsatellite-instabilityhigh-or-mismatch-repair-deficient-metastatic-colorectal-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/6c7a9e81-c87c-412e-b412-5ce54d8b5d9a/LinkedIn+Post+Template+Approvals+%26+News+-+2024-12-29T074153.561.png Press Releases - BMS Receives EU Approval for nivo+ipi plus for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-opdivo-subcutaneous monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/15a5ab01-fb33-40a4-99f2-1e0afd116f30/LinkedIn+Post+Template+Approvals+%26+News+-+2024-12-27T115458.092.png Press Releases - FDA approves OPDIVO Subcutaneous - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/tevimbra-approved-in-us-for-first-line-treatment-of-gastric-and-gastroesophageal-junction-cancers-in-combination-with-chemotherapy monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/5a94bbe7-ea90-43da-9d46-e3c5d221484b/LinkedIn+Post+Template+Approvals+%26+News+-+2024-12-27T090216.279.png Press Releases - TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-encorafenib-with-cetuximab-and-mfolfox6-for-metastatic-colorectal-cancer-with-a-braf-v600e-mutation monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/e57d0125-33cc-4129-8264-4e784c1c0db0/LinkedIn+Post+Template+Approvals+%26+News+-+2024-12-20.png Press Releases - FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/351c2840-1a71-413c-a576-01a93a938de2/LinkedIn+Post+Template+Approvals+%26+News+-+2024-12-18.png Press Releases - FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-unloxcyt-a-new-pd-l1-from-checkpoint-therapeutics-inc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/6b5dd163-abb4-410f-a540-23d2f38b19cb/LinkedIn+Post+Template+Approvals+%26+News+---.png Press Releases - FDA approves Unloxcyt, a new PD-L1 from Checkpoint Therapeutics, Inc. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-astrazenecas-durvalumab-for-limited-stage-small-cell-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4507425c-1be8-41ef-ba9d-453526258731/LinkedIn+Post+Template+Approvals+%26+News+%28100%29.png Press Releases - FDA approves AstraZeneca’s durvalumab for limited-stage small cell lung cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-zenocutuzumab-zbco-for-non-small-cell-lung-cancer-and-pancreatic-adenocarcinoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/23ba9dcf-19b7-461b-a8ba-1690f4bec2da/LinkedIn+Post+Template+Approvals+%26+News+%2899%29.png Press Releases - FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/novartis-kisqali-receives-european-commission-approval-in-a-broad-population-of-patients-with-hr/her2-early-breast-cancer-at-high-risk-of-recurrence monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9772310c-5b97-4b95-ac63-0bcd51b8d693/LinkedIn+Post+Template+Approvals+%26+News+%2898%29.png Press Releases - Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/beigene-adds-two-new-indications-for-tevimbra-as-a-first-line-treatment-for-advanced/metastatic-gastric-or-gastroesophageal-junction-cancer-and-esophageal-squamous-cell-carcinoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/17252e5d-5c49-4765-8b18-d3531123700e/LinkedIn+Post+Template+Approvals+%26+News+%2897%29.png Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647267827-AY318BZS1S1Z4F4R57EO/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-0.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647268213-6D7UE4Z36EOF49V83RIK/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-1.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647444609-M3BVJFMBQYNLZ6AF3NEZ/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-3.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647269168-82X6HNJVMR1K6PHAZ5GF/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-2.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647444638-DXIJNX5LIVLW70O4KMDD/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-4.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647481350-QA2VA0OUQYXMKC6KP9EZ/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-6.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647445952-9T78T9RKLYKBCGKFJIBD/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-5.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647481344-5V84XNTXHJ3CQI8RWK0X/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-7.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647576743-20ZTTCULIDFXGOGVKVQR/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-9.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647482770-7HGJ13Z2I8Z6OLQQKWG0/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-8.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647576552-F48Z60YLYYX0CIN1R5VN/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-10.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647603780-7RVYR6XRGXIOLFIS29XO/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-12.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647578166-EKEOLS5HN7X9XPPVTLJG/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-11.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647603722-YANHC8A13NPN3Y8P7R5N/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-13.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647638947-7E7XUCK1ESA09IOKFTHR/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-15.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647605318-CQPV5C7IJ33YH7JW68ZJ/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-14.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647638800-PZCU1BE5HML65W1E3HQ9/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-16.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647672536-F2YC2CFTNJREQJL590X1/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-18.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647640424-H6LSVKN5Q91H5TE2N4LA/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-17.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647672807-VZ6IW5NA73ZMUWJMH1YG/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-19.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647723699-UNUM7WNLJL47E8YMBZ7A/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-21.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647673929-19WKQDXLRIA5SMYZFPXS/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-20.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647724061-G9XEFD2J7WTMC5W8B9D6/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-22.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647772491-05603ACLDBZPZRSYSINQ/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-24.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647724929-1TJYLMY61GYOXGX030KJ/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-23.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647772292-Z5Z19SY2M02GP0V4Y6WK/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-25.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647799490-AQKNUSW16S72804I6QOH/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-27.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647773579-TU73VJPCXXMIK49QCLD1/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-26.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647799143-UOLLHI326TJRQCZFCGV7/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-28.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647847516-LVYZA9WZP72E2J9QEFSQ/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-30.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647800780-ILMS02JZ0X3T1YSF67XR/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-29.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647847374-J1U60NOXD7S7CO9ULCXF/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-31.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647953640-0MH7230V9SAOJC2FIYI5/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-33.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647848993-5YA86Y6GS20GPW2YH0SL/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-32.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647953774-HQYS00K3JPGOA8SZ8I7Q/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-34.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647979318-35JBCLQ6KO1H1G15EPFR/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-36.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647954597-BA3PHOK31RXEGUHNL4TT/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-35.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647979677-QUN3EC6A4F90MJRZMAC3/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-37.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648005700-Y8ZGZ61KYQRZJTH4SCKC/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-39.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732647980741-16KBY21ZA1ZN8XZA533X/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-38.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648005691-XXDTFRTWSH7C7DUCK3XB/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-40.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648026375-RUOMHXN0H4D5AO9DF8D3/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-42.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648006737-8WVETGJXORJFISP1HO28/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-41.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648026377-UOWGSB760ZREY5F93V26/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-43.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648051906-8SKJ1OLW9IWEZQUXI27C/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-45.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648027507-VZQC4HXU99VEVIGAS7W6/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-44.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648051917-D3HP3B7ZNRGOZHIKVA74/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-46.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648097640-LU0IFLPNC1N002SYGKR9/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-48.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648053209-UCW1Y4J4T532FOOOTJG1/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-47.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648097406-5U2NY6PMZPRJLX9ZVTOY/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-49.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648120430-VMKPAHUR0N5MBSZJYW95/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-51.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648098818-UF37X78R98ATMI6ZUWKS/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-50.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648120432-4VE5G2RACNOFIUHZHXNO/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-52.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648152680-97NNBIG1M211IEDRBOV8/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-54.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648122023-M6OS0BNRBRJE7Q6OH9YU/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-53.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648152548-BTFTR6PZV55IT2ESS2HE/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-55.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648173142-DNI7MR6G6JIMZXFU64BR/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-57.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648154087-FF3DF0CO4D5LZDQK05PL/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-56.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648172758-8334ZWFN74U1ZU92KC91/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-58.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1732648174165-X7SWF6ETQJBJ8NZ7L2TQ/Beigene+approval+--+Tevimbra%2C+INN-tislelizumab-images-59.jpg Press Releases - BeiGene adds two new indications for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma https://www.rxtrospect.com/press-releases/fda-accelerated-approval-for-zanidatamab-in-previously-treated-unresectable-or-metastatic-her2-positive-ihc-3-biliary-tract-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/2b245e55-a6f6-4d88-b1ce-e3a5d5bc61ba/LinkedIn+Post+Template+Approvals+%26+News+%2894%29.png Press Releases - FDA accelerated approval for zanidatamab in previously treated, unresectable or metastatic HER2-positive (IHC 3+) Biliary Tract Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/abbvie-receives-european-approval-of-elahere-mirvetuximab-soravtansine-for-the-treatment-of-platinum-resistant-ovarian-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/8a60051b-a39d-4637-b907-cc30bb7145bc/LinkedIn+Post+Template+Approvals+%26+News+%2893%29.png Press Releases - AbbVie Receives European Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-revumenib-for-relapsed-or-refractory-acute-leukemia-with-a-kmt2a-translocation monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/7613c108-cdc4-409d-9fc1-aaa7a50b90f9/LinkedIn+Post+Template+Approvals+%26+News+%2891%29.png Press Releases - FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-obecabtagene-autoleucel-for-adults-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/e0ebe840-126b-4e3b-a205-1aa3b48a81fe/LinkedIn+Post+Template+Approvals+%26+News+%2890%29.png Press Releases - FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grant-accelerated-approval-to-asciminib-scemblix-novartis-ag-for-adult-patients-with-newly-diagnosed-ph-cmlin-chronic-phase monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/b3a65504-9fad-4dd3-a8da-9efaa12be094/LinkedIn+Post+Template+Approvals+%26+News+%2889%29.png Press Releases - FDA grant accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Ph+ CML)in chronic phase - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-astellas-vyloy-for-first-line-gastric-or-gastroesophageal-junction-adenocarcinoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/541a2c90-7f6e-4bd9-bd16-b6b5270e6184/LinkedIn+Post+Template+Approvals+%26+News+%2887%29.png Press Releases - FDA approves Astellas’ Vyloy for first-line gastric or gastroesophageal junction adenocarcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-novocures-optune-lua-for-the-treatment-of-metastatic-non-small-cell-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/393daa2c-d820-48b2-8dd4-1e84c1c5d3fa/LinkedIn+Post+Template+Approvals+%26+News+%2886%29.png Press Releases - FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-genentechs-inavolisib-with-palbociclib-and-fulvestrant-for-endocrine-resistant-pik3ca-mutated-hr-positive-her2-negative-advanced-breast-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/67646d17-6efe-4a50-bbc5-8b5a89f3917f/LinkedIn+Post+Template+Approvals+%26+News+%2885%29.png Press Releases - FDA approves Genentech’s inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-neoadjuvant/adjuvant-opdivo-nivolumab-for-resectable-nsclc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/f97ae417-9727-43c1-8afe-3f2e48711c3f/LinkedIn+Post+Template+Approvals+%26+News+%2884%29.png Press Releases - FDA approves neoadjuvant/adjuvant Opdivo (nivolumab) for resectable NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-traditional-approval-to-lillys-retevmo-selpercatinib-for-adult-and-pediatric-patients-2-years-of-age-and-older-with-advanced-or-mtc-with-a-ret-mutation monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/e2509c50-c7bd-41c3-adc1-e700491741b0/LinkedIn+Post+Template+Approvals+%26+News+%2883%29.png Press Releases - FDA grants traditional approval to Lilly’s Retevmo (selpercatinib), for adult and pediatric patients 2 years of age and older with advanced or MTC with a RET mutation - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-osimertinib-for-locally-advanced-unresectable-stage-iii-nsclc-following-chemoradiation-therapy monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c251ba72-eaaa-449a-89de-5d7472cad924/LinkedIn+Post+Template+Approvals+%26+News+%2882%29.png Press Releases - FDA approves osimertinib for locally advanced, unresectable (stage III) NSCLC following chemoradiation therapy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-sanofis-sarclisa-in-newly-diagnosed-multiple-myeloma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c53bf869-a410-4cd3-ac59-15bd32702c8f/LinkedIn+Post+Template+Approvals+%26+News+%2881%29.png Press Releases - FDA Approves Sanofi's Sarclisa in Newly Diagnosed Multiple Myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-amivantamab-with-carboplatin-and-pemetrexed-for-nsclc-with-egfr-exon-19-deletions-or-l858r-mutations monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1f9b903f-9ced-4ee7-a9fd-16f7fcc5e619/LinkedIn+Post+Template+Approvals+%26+News+%2880%29.png Press Releases - FDA approves amivantamab with carboplatin and pemetrexed for NSCLC with EGFR exon 19 deletions or L858R mutations - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-pembrolizumab-with-chemotherapy-for-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/316040e4-81db-4b35-a25a-a17e3963fac5/LinkedIn+Post+Template+Approvals+%26+News+%2879%29.png Press Releases - FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-kisqali-with-an-aromatase-inhibitor-kisqali-femara-co-pack-for-early-high-risk-breast-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1fee9db7-ec03-46a2-bd46-833ded5c474e/LinkedIn+Post+Template+Approvals+%26+News+%2878%29.png Press Releases - FDA approves Kisqali with an aromatase inhibitor & Kisqali Femara Co-Pack for early high-risk breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-approves-astellas-padcev-in-combination-with-keytruda-for-first-line-treatment-of-advanced-urothelial-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c9361d3d-766a-4be5-a9f1-053fed1bc3a2/LinkedIn+Post+Template+Approvals+%26+News+%2877%29.png Press Releases - European Commission Approves Astellas’ PADCEV in Combination with KEYTRUDA for First-Line Treatment of Advanced Urothelial Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/ordspono-odronextamabr/r-follicular-lymphoma-or-r/r-dlbcl-both-3rd-line monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/17ae3ee0-5376-49f7-94e8-e43829429b80/LinkedIn+Post+Template+Approvals+%26+News+%2876%29.png Press Releases - Ordspono™ (odronextamab)R/R follicular lymphoma or R/R DLBCL, both 3rd Line - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-rybrevant-amivantamab-plus-lazcluze-lazertinib-in-first-line-chemotherapy-free-treatment-for-patients-with-egfr-mutated-nsclc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/ca57ee8c-742a-4d1c-bf5d-4cc2ab58676e/LinkedIn+Post+Template+Approvals+%26+News+%2875%29.png Press Releases - FDA Approves RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) in first-line chemotherapy-free treatment for patients with EGFR-mutated NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/tepkinly-epcoritamab-receives-second-european-commission-approval-for-the-treatment-of-adults-with-r/r-follicular-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/16164e53-86b9-49cf-b8ed-6240d5d974e2/LinkedIn+Post+Template+Approvals+%26+News+%2874%29.png Press Releases - TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with r/r Follicular Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-neoadjuvant/adjuvant-durvalumab-for-resectable-non-small-cell-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/000ba264-4ca9-4b0f-90bc-598530322a09/LinkedIn+Post+Template+Approvals+%26+News+%2873%29.png Press Releases - FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-approve-first-china-domestic-anti-pd-l1-mab-sugemalimab-as-first-line-treatment-for-non-small-cell-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/b08b4b6f-a3c6-4d2a-a7e9-630ec28f5aea/LinkedIn+Post+Template+Approvals+%26+News+%2872%29.png Press Releases - European Commission Approve First China Domestic anti-PD-L1 mAb sugemalimab as First-Line Treatment for Non-Small Cell Lung Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/citius-pharmaceuticals-receives-fda-approval-for-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-r/r-ctcl monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/2a7de1e3-dbb1-4374-b5ee-730ee781e107/LinkedIn+Post+Template+Approvals+%26+News+%2871%29.png Press Releases - Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for r/r CTCL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9c1af238-f360-43e9-9398-27ab95cd6715/table+approval+8-8-24.png Press Releases - Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for r/r CTCL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/483e02f2-8890-45f3-a285-b2ab6e253b5b/table+approval+8-8-24+legend.png Press Releases - Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for r/r CTCL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/first-fda-approval-for-a-systemic-therapy-for-patients-with-grade-2-astrocytoma-or-oligodendroglioma-with-a-susceptible-idh1-or-idh2-mutation monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/ada43699-991e-4821-8c90-04ad5b3a4636/LinkedIn+Post+Template+Approvals+%26+News+%2870%29.png Press Releases - First FDA approval for a systemic therapy for patients with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-first-gene-therapy-to-treat-adults-with-metastatic-synovial-sarcoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/229fb8dd-e850-4c50-a120-618b61227a87/LinkedIn+Post+Template+Approvals+%26+News+%2869%29.png Press Releases - FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-expands-endometrial-cancer-indication-for-dostarlimab-gxly-with-chemotherapy monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/35681199-9664-4d14-ac6e-99e0f8f84a6a/LinkedIn+Post+Template+Approvals+%26+News+%2867%29.png Press Releases - FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-darzalex-faspro-with-bortezomib-lenalidomide-and-dexamethasone-for-1st-line-multiple-myeloma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/43ab8955-3eea-4187-b998-18ff5cbf3833/LinkedIn+Post+Template+Approvals+%26+News+%2866%29.png Press Releases - FDA approves Darzalex Faspro with bortezomib, lenalidomide, and dexamethasone for 1st line multiple myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-accelerated-approval-for-genmabs-bi-specific-epcoritamab-for-3l-r/r-follicular-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/3ea43bd4-0271-4b0d-bb7c-94232c20d10b/LinkedIn+Post+Template+Approvals+%26+News+%2865%29.png Press Releases - FDA accelerated approval for Genmab’s bi-specific epcoritamab for 3L r/r follicular lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA accelerated approval for Genmab’s bi-specific epcoritamab for 3L r/r follicular lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-approval-for-takedas-fruzaqla-in-previously-treated-metastatic-colorectal-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/8fe6bd21-decf-43d9-9b21-349c00e7599a/LinkedIn+Post+Template+Approvals+%26+News+%2864%29.png Press Releases - European Approval for Takeda's FRUZAQLA in Previously Treated Metastatic Colorectal Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-krazati-adagrasib-cetuximab-for-kras-g12c-mutated-crc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/ef2c3eef-d0fd-411f-af6e-1674efc546aa/image-asset.png Press Releases - FDA grants accelerated approval to Krazati (adagrasib) + cetuximab for KRAS G12C-mutated CRC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA grants accelerated approval to Krazati (adagrasib) + cetuximab for KRAS G12C-mutated CRC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-durvalumab-with-chemotherapy-for-mismatch-repair-deficient-primary-advanced-or-recurrent-endometrial-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/870310c6-da98-4776-a8da-0934bb1be28e/LinkedIn+Post+Template+Approvals+%26+News+%2862%29.png Press Releases - FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-breyanzi-car-t-cell-therapy-for-r/r-mantle-cell-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/5e3b3e31-57f7-4e2a-93d6-f3a489540d94/LinkedIn+Post+Template+Approvals+%26+News+%2861%29.png Press Releases - FDA Approves Breyanzi CAR T Cell Therapy for R/R Mantle Cell Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA Approves Breyanzi CAR T Cell Therapy for R/R Mantle Cell Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-approve-opdivo-nivolumab-chemo-combination-for-first-line-unresectable-or-metastatic-urothelial-carcinoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d5c815e8-2674-4d63-af1c-5d6c6171950b/LinkedIn+Post+Template+Approvals+%26+News+%2860%29.png Press Releases - European Commission Approve Opdivo (nivolumab)-Chemo Combination for First-Line Unresectable or Metastatic Urothelial Carcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - European Commission Approve Opdivo (nivolumab)-Chemo Combination for First-Line Unresectable or Metastatic Urothelial Carcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/first-fda-approval-of-a-targeted-therapy-for-pediatric-patients-12-years-of-age-with-ret-alterations monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1717007011716-2AL43BZLSFCY0577IO8L/LinkedIn+Post+Template+Approvals+%26+News+%2858%29.png Press Releases - First FDA approval of a targeted therapy for pediatric patients < 12 years of age with RET alterations https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1717007019072-D3AHPIB73919MEFPMBYA/LinkedIn+Post+Template+Approvals+%26+News+%2859%29.png Press Releases - First FDA approval of a targeted therapy for pediatric patients < 12 years of age with RET alterations https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - First FDA approval of a targeted therapy for pediatric patients < 12 years of age with RET alterations - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-tarlatamab-for-extensive-stage-small-cell-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/92359925-57a2-4cd6-9bc6-839c8527687f/LinkedIn+Post+Template+Approvals+%26+News+%2857%29.png Press Releases - FDA grants accelerated approval to tarlatamab for extensive stage small cell lung cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA grants accelerated approval to tarlatamab for extensive stage small cell lung cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grant-accelerated-approval-to-car-t-breyanzi-in-3l-r/r-follicular-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/2253ebdc-7ddd-459b-bdae-29465f676127/LinkedIn+Post+Template+Approvals+%26+News+%2856%29.png Press Releases - FDA Grant Accelerated Approval to CAR-T Breyanzi in 3L r/r Follicular Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d41750b9-4b1b-4cb7-8f05-e679c825410e/LinkedIn+Cover+%282%29.png Press Releases - FDA Grant Accelerated Approval to CAR-T Breyanzi in 3L r/r Follicular Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/seagens-tivdak-confirms-benefit-in-recurrent-or-metastatic-cervical-cancer-with-disease-progression-on-or-after-chemotherapy-aa-pmr-fulfilled monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c34cd4a1-3556-4ab2-b354-bc587b9060f6/LinkedIn+Post+Template+Approvals+%26+News+%2855%29.png Press Releases - SEAGEN's Tivdak confirms benefit in recurrent or metastatic cervical cancer with disease progression on or after chemotherapy; AA PMR fulfilled - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - SEAGEN's Tivdak confirms benefit in recurrent or metastatic cervical cancer with disease progression on or after chemotherapy; AA PMR fulfilled - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/another-first-as-fda-grant-accelerated-approval-to-tovorafenib-for-patients-with-r/r-braf-altered-pediatric-low-grade-glioma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/49b76005-24fe-4ad8-8b29-b4056deca3dc/LinkedIn+Post+Template+Approvals+%26+News+%2854%29.png Press Releases - Another First as FDA grant accelerated approval to tovorafenib for patients with r/r BRAF-altered pediatric low-grade glioma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - Another First as FDA grant accelerated approval to tovorafenib for patients with r/r BRAF-altered pediatric low-grade glioma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/first-fda-approval-of-a-radiopharmaceutical-for-pediatric-patients-12-with-sstr-positive-gep-nets monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/0a0041b0-71dc-4324-a2af-7661b99b66a2/LinkedIn+Post+Template+Approvals+%26+News+%2853%29.png Press Releases - First FDA approval of a radiopharmaceutical for pediatric patients 12+ with SSTR-positive GEP-NETs - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - First FDA approval of a radiopharmaceutical for pediatric patients 12+ with SSTR-positive GEP-NETs - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-altor-biosciences-anktiva-nogapendekin-alfa-inbakicept-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d0e356db-d67b-4b99-93a3-c91e1dee466e/LinkedIn+Post+Template+Approvals+%26+News+%2852%29.png Press Releases - FDA approves Altor BioScience's Anktiva (nogapendekin alfa inbakicept) for BCG-unresponsive non-muscle invasive bladder cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA approves Altor BioScience's Anktiva (nogapendekin alfa inbakicept) for BCG-unresponsive non-muscle invasive bladder cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-genentechs-alecensa-as-first-adjuvant-treatment-for-people-with-alk-positive-early-stage-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d82da3ac-4674-4dc3-b569-f1e842c9f378/LinkedIn+Post+Template+Approvals+%26+News+%2851%29.png Press Releases - FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/carvykti-becomes-first-and-only-bcma-targeted-treatment-approved-by-the-us-fda-in-second-line-multiple-myeloma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/442589b5-7676-43e0-b3a5-1191bc641a06/LinkedIn+Post+Template+Approvals+%26+News+%2850%29.png Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1712591751969-CTVXLZ58TSO0NWGS8E2O/0001.jpg Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1712591765559-YX5WTLQYA7VNE69PYEK5/0002.jpg Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1712591777117-1ICBPFPVBVBNXGVAFAGP/0003.jpg Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1712591784677-C4AA2XSMH12PQLBZHIUF/0004.jpg Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1712591790688-KL5BSM5IL3NLEYZ0HR3B/0005.jpg Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1712591800307-Q0BLBZ4H7G1YWWL4E96I/0006.jpg Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1712591805932-Q1VLMWUM5GS6VCGC8KZG/0007.jpg Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1712591812560-PQ2TUMS9YWE76ABI9EQP/0008.jpg Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-tumor-agnostic-accelerated-approval-to-enhertu-for-unresectable-or-metastatic-her2-positive-solid-tumors monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9750ca87-8414-4b4d-8601-4251617ab124/LinkedIn+Post+Template+Approvals+%26+News+%2849%29.png Press Releases - FDA grants tumor agnostic accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA grants tumor agnostic accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-issued-crls-to-regeneron-for-odronextamab-bla-in-r/r-follicular-lymphoma-in-r/r-diffuse-large-b-cell-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4540da8b-6331-420e-9936-a44c2b2af578/LinkedIn+Post+Template+Approvals+%26+News+%2848%29.png Press Releases - FDA issued CRLs to Regeneron for odronextamab BLA in r/r follicular lymphoma & in r/r diffuse large B-cell lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA issued CRLs to Regeneron for odronextamab BLA in r/r follicular lymphoma & in r/r diffuse large B-cell lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-is-working-to-release-guidance-documents-that-regulate-use-of-artificial-intelligence monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/0ed9d115-73b7-426f-843c-f3002e525175/LinkedIn+Post+Template+Approvals+%26+News+%2847%29.png Press Releases - FDA is working to release guidance documents that regulate use of Artificial Intelligence - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA is working to release guidance documents that regulate use of Artificial Intelligence - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/meeting-of-the-oncologic-drugs-advisory-committee-meeting-announcement-15mar2024 monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/2118e417-a5b7-4bcf-84bc-7a83493ed4be/image-asset.png Press Releases - Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-zanubrutinib-for-r/r-follicular-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9f2843e3-37c5-4f9a-a889-5358a544c7de/LinkedIn+Post+Template+Approvals+%26+News+%2844%29.png Press Releases - FDA grants accelerated approval to zanubrutinib for r/r follicular lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA grants accelerated approval to zanubrutinib for r/r follicular lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-pfizers-inotuzumab-ozogamicin-for-pediatric-patients-with-acute-lymphoblastic-leukemia monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9ab849fd-03b6-4c96-91cf-7159a0d07161/LinkedIn+Post+Template+Approvals+%26+News+%2843%29.png Press Releases - FDA approves Pfizer’s inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA approves Pfizer’s inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-amivantamab-in-first-line-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications-converts-to-traditional-approval monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/44c4d9e8-9508-471d-97b5-e7a0c609c978/LinkedIn+Post+Template+Approvals+%26+News+%2842%29.png Press Releases - FDA approves amivantamab in first-line EGFR exon 20 insertion-mutated non-small cell lung cancer indications; converts to traditional approval - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA approves amivantamab in first-line EGFR exon 20 insertion-mutated non-small cell lung cancer indications; converts to traditional approval - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/iovances-amtagvi-lifileucel-receives-us-fda-accelerated-approval-for-advanced-melanoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/ba99c346-fc11-4fb0-afbf-e6a7322c7b1e/LinkedIn+Post+Template+Approvals+%26+News+%2841%29.png Press Releases - Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-converts-2021-accelerated-approval-of-tepotinib-emd-serono-inc-in-met-exon-14-nsclc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/ab6f3a04-c9c2-421d-a003-0355263e9a46/LinkedIn+Post+Template+Approvals+%26+News+%2840%29.png Press Releases - FDA converts 2021 accelerated approval of tepotinib (EMD Serono, Inc.) in MET exon 14 NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA converts 2021 accelerated approval of tepotinib (EMD Serono, Inc.) in MET exon 14 NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-irinotecan-liposome-for-first-line-treatment-of-metastatic-pancreatic-adenocarcinoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/2860558b-b536-4b12-b38a-b7e9c6673a0f/LinkedIn+Post+Template+Approvals+%26+News+%2839%29.png Press Releases - FDA approve Ipsen's Onivyde for the first-line treatment of metastatic pancreatic adenocarcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA approve Ipsen's Onivyde for the first-line treatment of metastatic pancreatic adenocarcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-full-approval-for-balversa-to-treat-locally-advanced-or-metastatic-bladder-cancer-with-select-genetic-alterations monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/3b608876-e756-4e52-8b38-da0d66466984/LinkedIn+Post+Template+Approvals+%26+News+%2838%29.png Press Releases - FDA Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-eflornithine-for-adult-and-pediatric-patients-with-high-risk-neuroblastoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/f729743d-ba72-4dd9-b702-fd8bfdf763ec/LinkedIn+Post+Template+Approvals+%26+News+%2837%29.png Press Releases - FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-grant-conditional-ma-to-pfizers-elrexfio-for-relapsed-and-refractory-multiple-myeloma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c496a385-8fa5-484d-91f2-d6af02d61058/LinkedIn+Post+Template+Approvals+%26+News+%2836%29.png Press Releases - European Commission Grant Conditional MA to Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - European Commission Grant Conditional MA to Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-pirtobrutinib-for-3l-cll/sll monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/6bcb814a-740c-4ed4-a320-6588614a41d6/LinkedIn+Post+Template+Approvals+%26+News+%2835%29.png Press Releases - FDA grants accelerated approval to pirtobrutinib for 3L CLL/SLL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA grants accelerated approval to pirtobrutinib for 3L CLL/SLL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-repotrectinib-for-ros1-positive-non-small-cell-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/81fdcddd-fb47-4717-93bc-fc629f668cc7/LinkedIn+Post+Template+Approvals+%26+News+%2834%29.png Press Releases - FDA approves repotrectinib for ROS1-positive non-small cell lung cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA approves repotrectinib for ROS1-positive non-small cell lung cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/truqap-capivasertib-plus-faslodex-approved-in-the-us-for-patients-with-advanced-hr-positive-breast-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/94f62ab3-b13a-4a7f-9d57-67a5ae9ee088/LinkedIn+Post+Template+Approvals+%26+News+%2833%29.png Press Releases - Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4f573a55-fb63-4a50-9fea-23662a3da093/LinkedIn+Post+Template+Approvals+%26+News+%2831%29.png Press Releases - BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-first-novel-pd-1-developed-in-china-us-trial-to-come-post-approval monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/6164373a-6add-4ff7-82f0-9b6363037079/LinkedIn+Post+Template+Approvals+%26+News+%2830%29.png Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752244532-16JSY26INWXGDVF1I7Z9/0001.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752259816-LPPR1U5PVT7GFFU6NL0B/0002.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752274764-3FU85HRDFYZPJJD95L5C/0003.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752287722-JR15ASV3IXVWP6MKO1H3/0004.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752301768-RPRT8W99OW7OLUGNOSBE/0005.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752313889-XN9T033Y2P0W9B3GZWJJ/0006.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752329162-N2GVQKWPNH2UC2FGO8S6/0007.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752341710-7OZAYNVA1I2WYU7TGAIK/0008.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752358101-R4TJNNZIG4RMVGF5FNA9/0009.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752376942-AUO8KXPEQBJD8UI71OAC/0010.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752423031-36RKUYKFLQH2ZAZIKYC3/0011.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752434915-KXYRES3D1L1DW6R649KO/0012.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752448825-H5UPQQE8OWY7ZYIQM20H/0013.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752461388-RNC2CKXUANPJ6UP2VPDR/0014.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752474677-GMHCKHK080ELGKE6IRUG/0015.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752487332-PA5YH1XJRDFHRHA62UES/0016.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752499940-53GQ50S4RJS0JDVZ90YF/0017.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752513403-4WQMT1SUQL9SXD179VWM/0018.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752526974-NNRHE0EE51MOQUTK36D1/0019.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752542871-60BK5F9BBUG9NZ4J2SQC/0020.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752554601-ZOG2SP70K245RSHH4WFM/0021.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752566796-OI59DGB5L2XTQN5HJE1B/0022.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752577877-CHMTA1GE0NR7317GH4TU/0023.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752590499-75I2XVMUJ6RHH0PD1MG4/0024.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752603912-0M4UB8984JR4C72VPKKW/0025.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1698752618099-2RCT2COHD06IVRHNB5GS/0026.jpg Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA approves first novel PD-1 developed in China; US trial to come post-approval - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-approval-for-abbvies-tepkinly-epcoritamab-for-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/bdd7eaeb-cc2a-4231-a806-29cf0d8f6031/LinkedIn+Post+Template+Approvals+%26+News+%2832%29.png Press Releases - European approval for AbbVie's TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - European approval for AbbVie's TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-has-approved-inaqovi-oral-decitabine-and-cedazuridine-for-the-treatment-of-adults-with-newly-diagnosed-acute-myeloid-leukaemia monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/404878b1-634e-4235-944c-cffac031c59c/LinkedIn+Post+Template+Approvals+%26+News+%2831%29.png Press Releases - European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/tevimbra-receives-european-commission-approval-for-the-treatment-of-advanced-or-metastatic-escc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c08393cc-7f90-41b2-84ee-b74082e534c0/LinkedIn+Post+Template+Approvals+%26+News+%2830%29.png Press Releases - TEVIMBRA Receives European Commission Approval for the Treatment of Advanced or Metastatic ESCC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - TEVIMBRA Receives European Commission Approval for the Treatment of Advanced or Metastatic ESCC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-pfizers-elrexfio-for-r/r-multiple-myeloma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/3052a3e7-7afe-4b1a-bb16-888e7de185a5/LinkedIn+Post+Template+Approvals+%26+News+%2829%29.png Press Releases - FDA grants accelerated approval to Pfizer's Elrexfio for r/r multiple myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA grants accelerated approval to Pfizer's Elrexfio for r/r multiple myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/us-fda-approves-talvey-talquetamab-tgvs-a-first-in-class-bispecific-therapy-for-the-treatment-of-patients-with-heavily-pretreated-multiple-myeloma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/fc193686-e64d-4e0d-ba26-8f7bb5159a32/LinkedIn+Post+Template+Approvals+%26+News+%2828%29.png Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678606482-E2H4HP5HCH3T1XI0IXID/0001.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678620040-8NBWO2SJBZ6IT5FQOKCN/0002.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678634703-F5Q57QD6N87A8RRJ54HJ/0003.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678634705-2CA8TFH7KYGLG36GYYUC/0004.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678657621-SB2A6F2LRPCGS44TR3IQ/0005.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678657730-4GF712KWPWZPZKFM95BF/0006.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678684051-QRKWPC7LMJDG45FV6517/0008.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678684275-V8JO8RPSQDXTJTVFCQSH/0007.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678712975-8SB4J48B5BMVCJPT07LG/0009.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678714697-DV08KW6D7CJ2M4A7A7FP/0010.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1691678711747-P0M4091YV4IWB7P0OCKK/0011.jpg Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/gavreto-confirms-benefit-in-nsclc-less-than-3-years-after-initial-accelerated-approval monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/ac6c07dd-77c7-479f-acaf-0a247ed4fcdc/LinkedIn+Post+Template+Approvals+%26+News+%2827%29.png Press Releases - Gavreto confirms benefit in NSCLC less than 3 years after initial accelerated approval - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - Gavreto confirms benefit in NSCLC less than 3 years after initial accelerated approval - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-daiichi-sankyos-nme-quizartinib-in-frontline-aml monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/a47a72e1-43e3-43c1-bb80-853a54fcf592/LinkedIn+Post+Template+Approvals+%26+News+%2826%29.png Press Releases - FDA Approves Daiichi Sankyo's NME quizartinib in frontline AML - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/LinkedIn+Cover+%282%29.png Press Releases - FDA Approves Daiichi Sankyo's NME quizartinib in frontline AML - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/eu-approves-roches-columvi-glofitamab-cma-for-r/r-dlbcl-orphan-maintained monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4b7d6fa8-56a0-4f56-9ae8-9a969b16e825/LinkedIn+Post+Template+Approvals+%26+News+%2825%29.png Press Releases - EU approves Roche’s Columvi (glofitamab) CMA for r/r DLBCL; Orphan Maintained - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - EU approves Roche’s Columvi (glofitamab) CMA for r/r DLBCL; Orphan Maintained - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-converts-blincyto-blinatumomab-to-full-approval-for-the-treatment-of-adults-and-pediatric-patients-with-mrd-positive-all monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/b853f893-ed9f-445f-9b21-fe47ad3c6e99/LinkedIn+Post+Template+Approvals+%26+News+%2825%29.png Press Releases - FDA converts BLINCYTO (blinatumomab) to full approval for the treatment of adults and pediatric patients with MRD-positive ALL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA converts BLINCYTO (blinatumomab) to full approval for the treatment of adults and pediatric patients with MRD-positive ALL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grant-accelerated-approval-for-genentechs-bispecific-antibody-columvi-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/64a89619-1621-42c1-b9df-957eafd84806/LinkedIn+Post+Template+Approvals+%26+News+%2824%29.png Press Releases - FDA Grant Accelerated Approval for Genentech’s Bispecific Antibody, Columvi in Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-olaparib-with-abiraterone-and-prednisone-or-prednisolone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/5a305f94-1204-45af-987b-4540e9a7cced/LinkedIn+Post+Template+Approvals+%26+News+%2823%29.png Press Releases - FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-ayvakit-avapritinib-as-the-first-and-only-treatment-for-indolent-systemic-mastocytosis monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/b3ea414b-c01b-4db6-8ac7-5af14cf29aac/LinkedIn+Post+Template+Approvals+%26+News+%2822%29.png Press Releases - FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1684845168402-PC7E4A25YP9DWQDF9M6E/0001.jpg Press Releases - FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1684845156870-R6BPYFURF20FN4AH8ZX3/0002.jpg Press Releases - FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1684845156445-PR2A6ENN7DEOQY5CSXNX/0003.jpg Press Releases - FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1684845165557-LT26BGS7X2WJPRSUJNW6/0004.jpg Press Releases - FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1684845161406-NH4M3IKM1XL3R8MHW1CM/0005.jpg Press Releases - FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approve-epkinly-epcoritamab-bysp-as-the-first-bispecific-antibody-to-treat-adults-with-r/r-dlbcl monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1b2c7f59-c7d2-4aa3-b50e-3229adbe6b8e/LinkedIn+Post+Template+Approvals+%26+News+%2821%29.png Press Releases - FDA Approve EPKINLY™ (epcoritamab-bysp) as the First Bispecific Antibody to Treat Adults with r/r DLBCL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/servier-receives-eu-approval-of-tibsovo-in-idh1-mutated-aml-and-idh1-mutated-cholangiocarcinoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/64bd4bbb-6a8c-44dd-816b-706c834dc91e/LinkedIn+Post+Template+Approvals+%26+News+%2820%29.png Press Releases - Servier receives EU approval of Tibsovo® in IDH1-mutated AML and IDH1-mutated Cholangiocarcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - Servier receives EU approval of Tibsovo® in IDH1-mutated AML and IDH1-mutated Cholangiocarcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-approves-bms-car-t-breyanzi-r/r-large-b-cell-lymphoma-after-one-prior-therapy monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/02ac8bb4-d0f5-447e-9081-5f4501a670e4/LinkedIn+Post+Template+Approvals+%26+News+%2819%29.png Press Releases - European Commission Approves BMS CAR T Breyanzi r/r Large B-cell Lymphoma After One Prior Therapy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - European Commission Approves BMS CAR T Breyanzi r/r Large B-cell Lymphoma After One Prior Therapy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-enfortumab-vedotin-ejfv-with-pembrolizumab-for-locally-advanced-or-metastatic-urothelial-carcinoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/52769017-eff6-4f12-9727-539db7dec10b/image-asset.png Press Releases - FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-dabrafenib-with-trametinib-for-pediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c4080e44-6e92-49ab-84de-32848f1706c4/image-asset.png Press Releases - FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/136ffeb1-7485-4545-9602-21a6a3deb71e/LinkedIn+Cover+%282%29.png Press Releases - FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-expands-early-breast-cancer-indication-for-abemaciclib-with-endocrine-therapy monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1678133244532-755BWB94WDCOZ1JPV2UY/LinkedIn+Post+Template+Approvals+%26+News+%2815%29.png Press Releases - FDA expands early breast cancer indication for abemaciclib with endocrine therapy https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1678133244439-F41CSFSDWQCG5UPAFJVZ/LinkedIn+Post+Template+Approvals+%26+News+%2816%29.png Press Releases - FDA expands early breast cancer indication for abemaciclib with endocrine therapy https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/da602c6d-a027-48e2-bc2c-ae64feb8ae43/image-asset.png Press Releases - FDA expands early breast cancer indication for abemaciclib with endocrine therapy - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-genentechs-lunsumio-a-first-in-class-bispecific-antibody-to-treat-people-with-r/r-follicular-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/69364054-69fe-447e-a615-df3c3228e222/image-asset.png Press Releases - FDA Grants Accelerated Approval to Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With R/R Follicular Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d41750b9-4b1b-4cb7-8f05-e679c825410e/image-asset.png Press Releases - FDA Grants Accelerated Approval to Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With R/R Follicular Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-first-gtx-for-the-treatment-of-high-risk-non-muscle-invasive-bladder-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/f9eb277a-8132-4d21-a1d3-d750e0cfbd6e/image-asset.png Press Releases - FDA approves first GTx for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d41750b9-4b1b-4cb7-8f05-e679c825410e/LinkedIn+Cover+%282%29.png Press Releases - FDA approves first GTx for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-adagrasib-for-kras-g12c-mutated-nsclc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/729f9619-cdac-47bd-aa2e-5b55c2243611/image-asset.png Press Releases - FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d41750b9-4b1b-4cb7-8f05-e679c825410e/image-asset.png Press Releases - FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-atezolizumab-for-alveolar-soft-part-sarcoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/5a703368-869c-4b52-b8f4-d943f16e6161/image-asset.png Press Releases - FDA approves atezolizumab for alveolar soft part sarcoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d41750b9-4b1b-4cb7-8f05-e679c825410e/image-asset.png Press Releases - FDA approves atezolizumab for alveolar soft part sarcoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-olutasidenib-for-r/r-aml-with-a-susceptible-idh1-mutation monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/16489aee-b484-491e-a9d8-3d1f64acbc6a/image-asset.png Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005127858-KRJ00EQXYALLA25DMCH2/0001.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005127936-LOE2Q2SBKUVJ6M42H6GC/0002.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005130399-SI6Q5INEXP13RCHEPVBD/0003.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005131333-5YF1EUMS1QCREG9HCFIG/0004.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005133063-6Q7KVFA7HCZ6WG3AOTJP/0005.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005133521-72KR4TT7XATM4QDUBPFI/0006.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005134953-ZY06O0JEYSZNDU173MW8/0007.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005136509-DHTSBXBG28MV1EOCILBY/0008.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005137147-08H4WNCG4YNTZR0LU90Y/0009.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005139270-DX3KYTO03D5TLKMZHM1X/0010.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005140025-V37YSTDX195OFOL878T7/0011.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005140987-RFG097I18GZCGO7BENN6/0012.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005142342-6N560T2ROOO2JZ9NNXNR/0013.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005164860-1GCO29WYQO028MZASDET/0014.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005143977-TJ0EA9GQ8JWI1YO58FI2/0015.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005145926-6CQL4FII375PE1AGZNAI/0016.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1670005147318-0R7H4R4U7UL9QGH4POK7/0017.jpg Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d41750b9-4b1b-4cb7-8f05-e679c825410e/LinkedIn+Cover+%282%29.png Press Releases - FDA approves olutasidenib for r/r AML with a susceptible IDH1 mutation - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-accelerated-approval-to-mirvetuximab-soravtansine-gynx-for-fr-positive-platinum-resistant-epithelial-ovarian-fallopian-tube-or-peritoneal-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/43839782-3e75-4ee0-a69f-3a8b48b61d55/image-asset.png Press Releases - FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/3b311e26-ed3e-4df1-ba76-53424ef5f428/LinkedIn+Cover+%282%29.png Press Releases - FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-seagens-adcetris-in-combination-with-chemotherapy-for-pediatric-patients-with-classical-hodgkin-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/77344c65-12f0-4152-9d3f-504ca87a38bb/image-asset.png Press Releases - FDA approves Seagen's Adcetris in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/6e340bb0-9990-4dd2-851f-f0e5ca4e062b/image-asset.png Press Releases - FDA approves Seagen's Adcetris in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/rxtrospect-remembers-2022 monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1d087587-1a53-46db-9587-31943480ac51/image-asset.png Press Releases - RxTROSPECT Remembers - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/8cdae93c-d649-45e6-8924-82ef7b263e44/LinkedIn+Cover+%281%29.png Press Releases - RxTROSPECT Remembers - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-cemiplimab-in-combination-with-platinum-based-chemotherapy-for-first-line-nsclc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/14458522-24af-45ba-8165-ceadd33ce57b/LinkedIn+Post+Template+Approvals+%26+News+%286%29.png Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978400297-FH6MSZ8SCGVWR07BNHY6/0001.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978395299-WGEHNNJ3RPPRSX3C0EZH/0002.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978400691-AKFG9ZY8LHTNE65RHZ7P/0003.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978410885-ABE5H00T3980YVFNZDY1/0004.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978411244-ZYX8IN3UGFBDAK09GW5B/0005.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978415596-MAO8QUAAC9TUOKTC1PMY/0006.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978417637-ANUVZZV7EGLXGEVQHNUO/0007.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978422017-7KAHLZA9IVW7C2GY4FYA/0008.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978423347-BDCO1OVSGQ5PSSOAHB4F/0009.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978428035-AHFJ4ZU83ISK8F4917T0/0010.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978428898-LVATPH1JSB2OPTK1FILB/0011.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978433166-Y75R8C3G77KWKKZDCP07/0012.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978432664-ASQZK6S940SGK97GUZ50/0013.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978436069-XPZ2HZ4P9X9YSF1XV7AA/0014.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978438313-215LT8WCENUP12UWNFKS/0015.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978440242-O3OIHFNBBQ3XI5US7ZCK/0016.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978444297-M5VVYJNRV1K16FEOXB88/0017.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978445079-AAV3BMYRDV2K9W511O0D/0018.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978449704-WG3Z4J2YXPN5YSY1YFAZ/0019.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978450097-P2DIZVZRAS4ZE8H53KBS/0020.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978454277-NELL3O920GQSHGB70O8N/0021.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978455469-9SG45YB2OAYOA9HHECDA/0022.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978465722-JLCBP9BGT4SGOVU8HHSX/0023.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978470632-TUGJI421U89MJLI96XXG/0024.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978475828-52VG0NTLIWIMRON7Z9HS/0025.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978476931-GIFC1HJ2YUUGVPMK5R7X/0026.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978482720-AMX5GP7FVOKHA3BFEM6G/0027.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978483288-GG5SD7MUQVO5Q4951K7X/0028.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978497218-965WP44AJBMAX1TQ7J59/0029.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978493009-GKJXVKBXT0L9FIU3DZ81/0030.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978503243-ORIQT6869GLG8YN0ICRC/0031.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978502549-6BICKA9XM36LJ7NZWJ27/0032.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978506525-XODYFR70JWUY1OZ2YOHQ/0033.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978505649-KPI1AK8YFIWKNAL1DQYA/0034.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978510699-RTEUO2LXH4Q3SCX8F5CB/0035.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978515771-JV3IVFZMNSOAR0NWP6B3/0036.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1667978521168-68YO5F1K3EUQY64L8ICS/0037.jpg Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/59ebdd63-923a-4733-83a3-f1bed3e1fc78/LinkedIn+Cover+%282%29.png Press Releases - FDA approves cemiplimab in combination with platinum-based chemotherapy for first-line NSCLC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-has-approved-enhertu-for-patients-with-the-her2-low-breast-cancer-subtype monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c7727389-32d9-4beb-ba30-127190ce19b3/image-asset.png Press Releases - FDA has approved Enhertu for patients with the HER2-low breast cancer subtype - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/7ff9cc34-ee5c-4e3a-b774-62325ad65968/image-asset.png Press Releases - FDA has approved Enhertu for patients with the HER2-low breast cancer subtype - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-bayer-darolutamide-for-metastatic-hormone-sensitive-prostate-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/7c14a700-d0ff-4703-8ba5-a7ce9033f0b2/image-asset.png Press Releases - FDA approves Bayer' darolutamide for metastatic hormone-sensitive prostate cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4edf96bf-0120-447f-9a17-3b11d7b0580c/image-asset.png Press Releases - FDA approves Bayer' darolutamide for metastatic hormone-sensitive prostate cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-crizotinib-for-alk-positive-inflammatory-myofibroblastic-tumor monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4d6fa938-c4da-4c15-b83c-970c6437c551/LinkedIn+Post+Template+Approvals+%26+News+%281%29.png Press Releases - FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/202dd90f-701a-45b8-acc3-0091273a307b/image-asset.png Press Releases - FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/yescarta-axicabtagene-ciloleucel-gains-eu-approval-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-3l-fl monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/169f2217-dfc5-4649-a6ce-08721cae6bf3/image-asset.png Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034355748-AJ10YI2NVOQ4NWWVKJ79/0001.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034362540-KNW41VPOWSZQL7PKWJUB/0002.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034364576-7AMZ4Q5Y9I1EA2V2IILH/0003.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034368511-BVDAYY5ZPNMSJ1JALXX1/0004.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034369463-TRRBN7QTNN5W95EXET2N/0005.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034372594-EUBFJOSZTS3UX5ZBTS61/0006.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034373158-JT7J28V2HXI6JEND48IY/0007.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034375652-PN8EP8H5E2V7CJYT15TV/0008.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034376466-6PIDEGYJ2Z25NNGFJ6K7/0009.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034378713-GZPW18V105ANPFMHWPLB/0010.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034380357-KCLM2ISH6RHVV26YAHJN/0011.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034381698-MMWS9IGRR5UPJ9SXSA5N/0012.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034402295-UH2ETVPD1CJNNHJRN4T0/0013.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034406668-F4EJ6RTH9L1JB344GYXO/0014.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034409049-N5Q31S2S8CGI1E9ZINFT/0015.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034411681-9WA78LUPPLN7TBBA05F4/0016.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034420417-0G3HIC85CLLGFNGHIAF7/0017.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034433129-IS2OYKJ1TUPE1YLHNSPA/0018.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034436141-L4BBT6H9TH79LEK12K8A/0019.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034446245-X6LO2TM00EEQSZZY401N/0020.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034446994-XJNPTBY0R8SA3SSVCG08/0021.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034451189-D163P2SYJDL1H7OAYDUG/0022.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034451353-QV36HMKQNJ3BTY8RJQEV/0023.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034452527-509QC96JBWWXP7RCEQST/0024.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034452978-OSZWCC4KA8YOFJLXRDSM/0025.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034455091-2IGCYNL4JMJTS5IWX5Z6/0026.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034457499-3E42EAKLIK836E5IUULI/0027.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034458843-PYMQPW89NO2FCASTNOO4/0028.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034460739-EOWOG6ZS643AOU4RM9AQ/0029.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034462428-LB1TFPFE6CMTSK54P9WL/0030.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034465790-Q76F6VZSUSE7137TKZC9/0031.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034465936-OTYE7CB7PQY9UNVTUTEE/0032.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034467128-NH3K0R3OAK126K1NPJ8V/0033.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034468719-3X4QZ7JZBBIS6F6CMDFR/0034.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034468863-S89464EYWMX070EP1D0F/0035.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034475767-O5O808ARXKIL6DOL6QHW/0036.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034476327-VEXKZSFVXMYN48M3FUHG/0037.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034486224-3X2ZHCBX1K75WTBBWB1B/0038.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034488719-7NEA4GSMKP0VQGOR4FHH/0039.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034493711-UXE5LT2YD64GLXE1E2WU/0040.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034494288-50SD34142KC8R50P0KVG/0041.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034495709-YKHQO6P6V53D9ZQ1XR2I/0042.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034495917-0IGKWQL1ZCQ1BB5NGE14/0043.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034498740-ORY5K9KUEW1KO8QKKFI1/0044.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1657034497754-DE82T9LUDT88CX61IAD1/0045.jpg Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/6d270ade-4ec9-4b21-b3fa-fb0488dc19ef/image-asset.png Press Releases - Yescarta® (axicabtagene ciloleucel) gains EU approval for the treatment of adult patients with relapsed or refractory (3L+) FL - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-novartis-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/ac48263e-1f54-4a0b-b772-403e40f0c21f/image-asset.png Press Releases - FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-grants-regular-approval-to-fam-trastuzumab-deruxtecan-nxki-for-breast-cancer-israel-included-for-the-first-time-in-orbis-approval monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/0411789b-9cf6-41fb-9764-1fd7bd5e1f41/image-asset.png Press Releases - FDA grants regular approval to fam-trastuzumab deruxtecan-nxki for breast cancer; Israel included for the first time in Orbis-approval - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/0437f5ba-1ff7-4dd4-b9d5-c9073189fd33/image-asset.png Press Releases - FDA grants regular approval to fam-trastuzumab deruxtecan-nxki for breast cancer; Israel included for the first time in Orbis-approval - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/tg-therapeutics-announces-voluntary-withdrawal-of-the-bla/snda-for-u2-to-treat-patients-with-cll-and-sl-ukoniq-aa-withdrawn-from-market monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/ecbcc412-1aa1-436c-8fae-2beb128a0b74/image-asset.png Press Releases - TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SL; UKONIQ AA withdrawn from market - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4ccebeb9-aaad-4e76-a6ea-87d5e0f860fa/image-asset.png Press Releases - TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SL; UKONIQ AA withdrawn from market - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-approval-new-indications-for-opdivo monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d47eeb2f-0395-4080-8e47-8a1fc3409134/LinkedIn+Post+Template+Approvals+%26+News+%2810%29.png Press Releases - European Commission Approval New Indications for Opdivo - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/bristol-myers-squibb-receives-european-commission-approval-for-car-t-cell-therapy-breyanzi-lisocabtagene-maraleucel-for-certain-forms-of-relapsed-or-refractory-large-b-cell-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/fd85493d-4a9b-4e53-bf48-58213f5b8d88/image-asset.png Press Releases - Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/84498a3e-3309-460e-925b-deb1438ea38a/image-asset.png Press Releases - Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-axicabtagene-ciloleucel-for-second-line-treatment-of-large-b-cell-lymphoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/a0a181f2-0648-44c2-8b53-148420481457/image-asset.png Press Releases - FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/158b6c74-be65-4fa5-9cbd-8c8c0997aa28/image-asset.png Press Releases - FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-olaparib-for-adjuvant-treatment-of-high-risk-early-breast-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9e1b6726-246d-4753-8014-096a7fff001f/image-asset.png Press Releases - FDA approves olaparib for adjuvant treatment of high-risk early breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1b78cd8d-f112-4e04-b51e-b45e0168bfba/image-asset.png Press Releases - FDA approves olaparib for adjuvant treatment of high-risk early breast cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/2022/3/10/tg-therapeutics-announces-odac-22-april-2022 monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/2769c655-c966-44c1-9985-6d689e84c630/image-asset.png Press Releases - TG Therapeutics Announces ODAC, 22 April 2022 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/48897e92-f223-4ae2-9add-89720fbe6e70/image-asset.png Press Releases - TG Therapeutics Announces ODAC, 22 April 2022 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-ciltacabtagene-autoleucel-for-relapsed-or-refractory-multiple-myeloma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c3c80287-05dd-40ea-a864-2fce624b9ba7/image-asset.png Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228602082-8O8K6ECMB0WUFBDP9J1P/0001.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228593385-5AEJOMPLNHT9DXACQFVQ/0002.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228604743-FYQQ39V6JHX8H51MLOK9/0003.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228609298-B16LBAQDSD08NYT9F15Q/0004.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228610337-MVI4MYBG2A999Y7R7R3W/0005.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228611785-MBRO9JZO4GS00ZU10B5Y/0006.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228612533-98GWQEVIO59C8TEEJO29/0007.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228613745-7570N07KHPMILM7TVM0O/0008.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228614962-66CS8LROOLB9CRNBPH6E/0009.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228615628-HLOCVZ76L68O6RQJU00I/0010.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228617378-W0K4N2VGUW2H82KU74YJ/0011.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228618969-GO5L05LH8M3FNLFAHGXW/0012.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228620840-Z1VUTUF6WIR9E56GKYJ0/0013.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228622327-HJA3ACF9LM564J0D391S/0014.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228623538-82MC8MS1BW0QIS52NZQI/0015.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228625523-ERBIUTMOGSPE5QS1NO0L/0016.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228626507-X1JPWIZ0ZPNUGSUXEMS7/0017.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228628604-VEX37S4GCFLA9DAV17FD/0018.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228628999-265SRQID4ZOU1W1H9PDW/0019.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228631718-AAUQUCJRA8GBY4J0599L/0020.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228631801-5NYX2RF9MRTNSIS3XLRA/0021.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228633757-N28II4GLWPLWDYO99ZZV/0022.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228636447-DRG3HCRNGZCMKHIBSSCT/0023.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228636983-BDLTK6KV7QT0D793LJWU/0024.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228639946-XDV16RYZO1A73OOBUXHC/0025.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228639849-F66UXWIX6Z2A0GT57AEZ/0026.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228642350-57XCM8ZCILIZXT6O3HFX/0027.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228642816-LQHL9Q5QZCPRD5YOITO7/0028.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228643909-P5NOU22DF0R9T13G71EV/0029.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228645131-DF2HBI700UL6RVVD02JS/0030.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228646219-VEWIA31PEUNYSB6LFAYV/0031.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1646228647329-W44MJDQHYDRLTY9ATOXE/0032.jpg Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/7a331d61-d3d2-4d58-ae5a-0a45c0c520eb/image-asset.png Press Releases - FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-approves-lorviqua-lorlatinib-as-a-first-line-treatment-for-alk-positive-advanced-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/762b33ec-1e0e-4800-9d20-f11e2d0ea897/image-asset.png Press Releases - European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/760cfcc2-93cd-41b2-bab6-3f1b724ecff4/image-asset.png Press Releases - European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc-following-surgery monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/a1e1f5ef-0d0b-43e5-afe4-d9eb52265a39/image-asset.png Press Releases - European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9245020d-836b-4e2e-bbf5-283be1953ca4/image-asset.png Press Releases - European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/immunocore-announces-fda-approval-of-kimmtrak-tebentafusp-tebn-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/64b4c4bf-3f0b-4b0c-8117-eddf85b98493/image-asset.png Press Releases - Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/b79a8853-86bf-408a-be9d-b6ea33772887/image-asset.png Press Releases - Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/gilead-withdraw-accelerated-fl/sll-zydelig-indications-from-us-market-cites-enrollment-challenge monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/165c2291-437a-4923-ab09-480982621f3c/image-asset.png Press Releases - Gilead withdraw accelerated FL/SLL Zydelig® indications from US market; cites enrollment challenges - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/b79a8853-86bf-408a-be9d-b6ea33772887/image-asset.png Press Releases - Gilead withdraw accelerated FL/SLL Zydelig® indications from US market; cites enrollment challenges - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/shout-out-congratulations-to-friends-of-cancer-research-on-their-25-year-anniversary monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/cecd6b3c-c8ab-4d05-86b9-3cc92c3de507/LinkedIn+Post+Template+Shout+Out.png Press Releases - Shout Out: Congratulations to 'Friends of Cancer Research' on their 25 year anniversary - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/european-commission-grants-janssen-conditional-ma-for-rybrevant-amivantamab monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/c80f83d3-b7cf-40af-adac-d985bed8d8aa/image-asset.png Press Releases - European Commission Grants Janssen Conditional MA for RYBREVANT (amivantamab) - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-rituximab-plus-chemotherapy-for-pediatric-cancer-indications monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1ea54ba5-ff00-4f90-8388-31380f1fa194/Approval+03+Dec+21.png Press Releases - FDA approves rituximab plus chemotherapy for pediatric cancer indications - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-darzalex-faspro-kyprolis-and-dexamethasone-for-multiple-myeloma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/d97f09ef-e91a-46a9-abe0-ca5466d5e58b/image-asset.png Press Releases - FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/tg-therapeutics-inc-plans-to-host-odac-meeting monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/478e7669-ed2e-4e34-bada-6939df78d595/News+update+30+Nov.png Press Releases - TG Therapeutics, Inc. plans to host ODAC meeting in connection with its review of the pending BLA/sNDA for the combination of ublituximab and UKONIQ® - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/trodelvy-sacituzumab-govitecan-approved-in-europe-for-2nd-line-tnbc monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1f75f1c5-f2cd-497a-b632-797a2996bac8/image-asset.png Press Releases - Trodelvy (sacituzumab govitecan) Approved in Europe for 2nd Line TNBC - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/beigenes-brukinsa-zanubrutinib-approved-in-eu-for-waldenstrms-macroglobulinemia monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/fb853574-4a16-42d9-8de2-616b6ffd246e/image-asset.png Press Releases - BeiGene's BRUKINSA (zanubrutinib) approved in EU for Waldenström’s Macroglobulinemia - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/fda-approves-sirolimus-protein-bound-particles-for-malignant-perivascular-epithelioid-cell-tumor monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/f7427c84-16d8-4166-b1c9-19f1da0b291e/FDA+Approval+23+Nov+21.png Press Releases - FDA approves sirolimus protein-bound particles for malignant perivascular epithelioid cell tumor - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/2021/11/21/european-commission-approves-roches-gavreto-pralsetinib-for-the-treatment-of-adults-with-ret-fusion-positive-advanced-non-small-cell-lung-cancer monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/a50ef439-e9d1-4163-9578-b96be1260519/image-asset.png Press Releases - European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/press-releases/2021/11/5/fda-approves-pembrolizumab-for-adjuvant-treatment-of-renal-cell-carcinoma monthly 0.5 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/5eb19604-f8f2-4315-adaf-d71fb1e1ce47/image-asset.png Press Releases - FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/solution-partner-terms-conditions daily 0.75 2021-07-30 https://www.rxtrospect.com/images daily 0.75 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1612395507303-7XN4DG7V8DB4VZV1W7ZU/Close.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1618687531525-QW3AVA4XT6DG2UQLAC00/LinkedIn+Signature+Block.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1619185695455-9ZUI43QBJR3V9WSL27NV/Video+Thumbnail.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1621440961582-5JI6JAW4ZHZO3FMF2WGH/Email+Thumbnail.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1643216822469-PDZ5E13T1PBG2C6T9OLN/Brochure+Image+HTML+image+for+email.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1643591042762-8FTI5QHPR89GE62KRSLQ/Thank+you+for+choosing+RxTROSPECT+-+%281%29.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1689695722557-9BY55T64NXPP3ZA9HICM/RxTROSPECT+Brochure+%28Digital%29.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1727998652391-FHD44SKC05FBHCHZPMTW/Thank+you+for+choosing+RxTROSPECT.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/b3278322-00c0-4381-abc1-a9888fc42baa/RxTROSPECT_logo_gold.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/df4f0c4b-ef11-4373-8c1d-012f7eadd8d0/Email+Signature+Blocks+-+Images+-+Referral+Program.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9c65259c-e308-4a1a-bcbb-c1909c007d01/Email+Signature+Blocks+-+Image+-+Follow+LinkedIn.png Images https://www.rxtrospect.com/contact daily 0.75 2025-01-27 https://www.rxtrospect.com/rxtrospect-analytics daily 0.75 2025-02-01 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265771874-UFKYM1AE3NKPF20SLN10/RxTROSPECT%2BBackground%2B%2528wide%2529.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265758256-FKVU9RJT27CPTHXCC6CD/RxTROSPECT%2BFade%2B-%2BLeft%2Bto%2BRight.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265759620-W8MGS841P6KQJL6KRWG2/RxTROSPECT%2BFade%2B-%2BRight%2Bto%2BLeft.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265759786-9CGKN9UPL1WR5YPCEFGJ/RxTROSPECT%2Bimages.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265762378-XPFG2V0UEFTL0W5B00SH/RxTROSPECT%2BBackground%2B%2528500%2Bx%2B389%2Bpx%2529%2B%25281%2529.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265763873-OHKEOAQTCV6AXF0G2LIA/Icon%2BVectors%2B-%2BHomepage%2B-%2BTime.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265758905-19AR9QTZ800AX442WYJF/RxTROSPECT%2BBackground%2B%2528500%2Bx%2B288%2Bpx%2529.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265760599-R9QKNMZ5YKHSGQD3AXSP/RxTROSPECT%2B--%2BIntelligence%2BEcosystem.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265762200-90BGB0WTIB0P09QJACFD/Icon%2BVectors%2B-%2BAnalytics%2B-%2BSystem.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265764932-SY33PSC5AWXX3L3RILQ4/RxTROSPECT%2BOverlay https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265769706-XXXQ3LJ6XE3GGEN4GXB8/RxTROSPECT%2BOverlay%2BStat%2Bimages.png https://www.rxtrospect.com/rxtrospect-discovery daily 0.75 2025-01-21 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265785658-35MGRU2IBSL76D536LYF/RxTROSPECT%2BDiscovery https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265783387-UDQAF81B2TOU3RFPQBPO/RxTROSPECT%2BFade%2B-%2BLeft%2Bto%2BRight.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265784473-ADTI349BNGT20MVZKZK8/RxTROSPECT%2BFade%2B-%2BRight%2Bto%2BLeft.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265786529-NJINR734UV241HRJL5FY/RxTROSPECT%2BDiscovery%2B-%2BClickUp%2BDoc%2Bfor%2BCustomers.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265788627-9KUOJXWO3Q4LE93SGTC0/RxTROSPECT%2BBackground%2B%2528500%2Bx%2B389%2Bpx%2529.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265789832-913VGIRF2EWX9HLTAPL0/RxTROSPECT%2Bvector https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265785181-VT02PWG5SFRH5PW6OJE8/RxTROSPECT%2BBackground%2B%2528500%2Bx%2B288%2Bpx%2529%2B-.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265786435-8J0XFU06JUSF0FY35E7E/RxTROSPECT%2B--%2BIntelligence%2BEcosystem.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265787700-0V0JQWA561I8L222YVR4/RxTROSPECT%2Bvector https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265786028-DF62QZVYI741KU384RPM/RxTROSPECT%2BBackground%2B%25281800%2Bx%2B1200%2Bpx%2529%2B%25281%2529.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265788550-XQUU4IJ81U3I9TDIITVK/RxTROSPECT%2BOverlay%2BStat%2Bimage%2B-%2BDiscovery.png https://www.rxtrospect.com/endpts-june-2023-clone-1736266203773 daily 0.75 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266221538-XPZNDR6ZE6KGM7THU2EJ/7.png RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266223209-SH8726EEI2ZP72AVRMKV/8.png RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266224693-TH7OV9SFA5KAHDAUOJ67/Approval+Times.png RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266225995-94QH29PL9SVIDJ7SAP7B/Approvals+Per+Year+-+1920+x+932+px.png RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266228086-3HGY0XRLABXAQLNUJS51/Condition+Overview.png RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266229349-CR721U3MIRS6EBN20KTQ/Pivotal+Study+-+Original+vs+Supplement.png RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266230647-2U5EKR68KMU4Y45Q14ZO/Pivotal+Study+Size+BTD+AA.png RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266232521-MU41KBRD36ZZFAGI5RBW/Pivotal+Study+Size.png RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266206836-0RLOU125Y6NPP02BUCKU/image-asset.gif RxTROSPECT - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266205466-5IOAXU4UHALCJFJ840SA/RxTROSPECT%2BFDA%2BApprovals%2BOncology%2BAnalytics RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266207052-J9M1HGFHDBPMWORDIRKK/RxTROSPECT%2BFDA%2BApprovals%2BOncology%2BAnalytics RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266208451-TR6MWDWV5CYED2XLPBKX/RxTROSPECT%2BFDA%2BApprovals%2BOncology%2BAnalytics RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266232575-1SR871AA79MQDQQO5UUA/0001.jpg RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266234787-JRWRQ2JYBHCMC8J4QGX1/0002.jpg RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266236641-EGZ1NU5QUARC8CVT8FX3/0003.jpg RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266238059-6PHKJS4OLGHONWTSQ0K3/0004.jpg RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266240125-OS9BL58HT0UY24V1OQN7/0005.jpg RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266241856-ZXFQFD7TP5QDR5U327IV/0006.jpg RxTROSPECT https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266210797-TSXMVA8J65RPYO51D9YW/image-asset.png RxTROSPECT - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266205513-S9FPW8H096789TSYEQV5/image-asset.png RxTROSPECT https://www.rxtrospect.com/use-cases-1 daily 0.75 2025-01-07 https://www.rxtrospect.com/about-clone-1736266244740 daily 0.75 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266247139-LIUNDAC4MF57NPKD7054/RxTROSPECT%2B-%2BOur%2BJourney.png About Us - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266248840-XTAFZ2ER1C30GT3P1ZY5/About%2BUs.png About Us - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266250802-SQ9LWS25HNLB9UOPSFP9/image-asset.png About Us - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266251985-VJH4KHG0DOCB0V1GFLEE/testimonial%2B%25282%2529.png About Us - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.rxtrospect.com/get-a-demo-clone-1736266268123 daily 0.75 2025-01-07 https://www.rxtrospect.com/legal-clone-1736266676518 daily 0.75 2025-01-07 https://www.rxtrospect.com/images-clone-1736266683051 daily 0.75 2025-01-07 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266685951-Z2EUYXZ1EVZUDRR399LK/Close.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266686985-0FLOOH6F9HB26E00RI3Z/LinkedIn+Signature+Block.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266688776-8WTZJH56DXLW1FLLWGGD/Video+Thumbnail.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266691037-4FY37C8GRIRXSDIEPWKU/Email+Thumbnail.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266697690-Y4T92FVH999RET0SCIJE/Brochure+Image+HTML+image+for+email.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266702178-2DUYCBOKA1GITTCEJ7KL/Thank+you+for+choosing+RxTROSPECT+-+%281%29.png Images https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736266706896-8BWCGMG0RD6GWC7AS5TB/RxTROSPECT+Brochure+%28Digital%29.png Images https://www.rxtrospect.com/news daily 0.75 2025-01-29 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265771874-UFKYM1AE3NKPF20SLN10/RxTROSPECT%2BBackground%2B%2528wide%2529.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265605315-G4V38MN8ZJAI8A42GV29/RxTROSPECT%2B-%2BNews.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/cfb99a0a-31f7-40f6-93ae-31cea1c7e02d/Animated+Gray+RxTROSPECT+logo.gif https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/5b78863a-26a7-4cc3-8083-81eb2feb49ec/Dots.png https://www.rxtrospect.com/referral-program daily 0.75 2025-02-18 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/9632ffc2-c8fc-4bd9-82cc-fe26422e4dc5/Referral+page https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/4daca826-160c-40a9-84bc-d6b8eba0ca2f/Referral+page+-+How+it+works+%281400+x+1200+px%29.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/8cdd48cf-408e-4914-abf2-66ce726fc9c7/Referral+page+-+Thank+you%281400+x+1200+px%29.png https://www.rxtrospect.com/welcome daily 1.0 2025-03-11 https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265604571-0SUVV0BI0HYPAGKFZ1YI/RxTROSPECT%2BFade%2B-%2BRight%2Bto%2BLeft.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265603435-PXCBFH1O171YN3UGNARA/RxTROSPECT%2BFade%2B-%2BLeft%2Bto%2BRight.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265603399-OH33G6IQ3S1LBVIWXA0R/RxTROSPECT%2BBackground.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265604602-METCULGHRDVBXIFTZ0B3/RxTROSPECT%2BBackground%2B%2528500%2Bx%2B110%2Bpx%2529.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265605654-OVYDMKS11IQGLOHC1ULQ/RxTROSPECT%2BBackground.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265606464-MPNYG2PNXW0MS74EDXJO/RxTROSPECT%2BBackground%2B%2528500%2Bx%2B110%2Bpx%2529.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265603620-0OBFMIB50OP7N59TPTKT/Rx%2BThought%2BLeadership.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265605200-P8E7K78RI0E9HX7OQ920/Rx%2BTiming.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265606235-1CSWR40OMZABP28I6SCV/Rx%2BPerformance.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265605315-G4V38MN8ZJAI8A42GV29/RxTROSPECT%2B-%2BNews.png https://images.squarespace-cdn.com/content/v1/587c04b8f5e231c4f3731c40/1736265608719-Z0AIVVGP27PX5PXN6ECX/RxTROSPECT%2B-%2BLinkedIn https://www.rxtrospect.com/us-regulatory-approvals daily 0.75 2025-03-03 https://www.rxtrospect.com/eu-regulatory-approvals daily 0.75 2025-03-03 https://www.rxtrospect.com/data-integration-for-regulatory-teams daily 0.75 2025-03-03 https://www.rxtrospect.com/tools-for-digital-regulatory-strategists daily 0.75 2025-03-03 https://www.rxtrospect.com/turnkey-and-scalable-intelligence-platform daily 0.75 2025-03-03 https://www.rxtrospect.com/full-access-data-integration-for-ds-teams daily 0.75 2025-03-03 https://www.rxtrospect.com/secure-platform-for-your-authorized-staff daily 0.75 2025-03-03 https://www.rxtrospect.com/enhanced-decision-making-and-reduced-risk daily 0.75 2025-03-03 https://www.rxtrospect.com/rapid-answers-for-the-board-and-executive-team daily 0.75 2025-03-03 https://www.rxtrospect.com/data-for-your-internal-company-knowledge-hub daily 0.75 2025-03-03